胃癌组织DNA拓扑异构酶2α等8种分子的蛋白表达与脉管侵犯的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (10324 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 研究DNA拓扑异构酶2α（TOP2A）等8种分子在伴脉管侵犯胃癌患者中的蛋白表达。方法: 回顾性分析242例胃腺癌患者的临床资料，免疫组化检测其石蜡包埋肿瘤组织中TOP2A、微管蛋白β3、胸苷酸合酶(TS)、非转移蛋白23（NM23）、P糖蛋白、增殖标记Ki-67、切除修复交叉互补酶1（ERCC1）及人类表皮生长因子受体2（HER2）的蛋白表达，比较有和无脉管侵犯者之间上述分子标志物表达的差异。结果： 81例（33.5%）患者有脉管侵犯，其中女性、肿瘤最大径≥5 cm、伴神经侵犯及TNM分期Ⅲ-Ⅳ期患者的比例均显著高于无脉管侵犯者（P<0.05）。有脉管侵犯者的TOP2A高表达率（89.3%）显著高于无脉管侵犯者（72.9%，P<0.05），而微管蛋白β3、TS、NM23、P糖蛋白、Ki-67、ERCC1及HER2的高表达率在两组间差异均无统计学意义（P>0.05）。亚组分析显示，有和无脉管侵犯者之间TOP2A高表达率的差异主要出现于女性（100% vs 72.2%，P=0.045）和组织学分级Ⅲ级的患者中（89.3% vs 67.6%，P=0.040）。结论：有脉管侵犯胃癌患者的TOP2A高表达率显著高于无脉管侵犯者，提示TOP2A在脉管侵犯中起作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：胃癌, 脉管侵犯, 分子特征, DNA拓扑异构酶2α

Abstract：Objective: To investigate the protein expression of eight molecules including DNA topoisomerase 2α (TOP2A) in gastric cancer patients with lymphovascular invasion. Methods: A retrospective study was conducted in 242 patients with gastric adenocarcinoma. The protein expressions of TOP2A， tubulin β3, thymidylate synthase(TS), nonmetastatic protein 23(NM23), Pglycoprotein, proliferation marker Ki67,excision repair crosscomplementation group 1(ERCC1) and human epidermal growth factor receptor 2(HER2) in paraffinembedded tumor tissues were detected by immunohistochemistry and were compared between patients with and without lymphovascular invasion. Results: Lymphovascular invasion was detected in 81 patients (33.5%), and the proportions of female patients, patients with the longest diameter of tumor≥5 cm, nerve invasion and TNM stages of Ⅲ-Ⅳ were significantly higher in these patients than that in patients without lymphovascular invasion(P<0.05). The high expression rate of TOP2A protein in patients with lymphovascular invasion（89.3%） was significantly higher than that in those without lymphovascular invasion(72.9%，P<0.05), and this difference was mainly found in subgroups of female(100% vs 72.2%，P=0.045) and histological grade of Ⅲ (89.3% vs 67.6%，P=0.040). The high expression rates of tubulin β3, TS, NM23, Pglycoprotein, Ki67, ERCC1 and HER2 protein were not significantly different between these two groups(P>0.05). Conclusion: Gastric cancer patients with lymphovascular invasion had a significantly higher expression rate of TOP2A protein compared with those without lymphovascular invasion, suggesting the role of TOP2A in lymphovascular invasion.

收稿日期: 2017-08-08

基金资助:

国家自然科学基金资助项目（81301765，81402485）；江苏省青年医学重点人才项目（QNRC2016829）；镇江市科技计划项目（SH2013079，SH2015054，SH2016038）

通讯作者: 王德强（通讯作者），主治医生，博士，E-mail: deqiang_wang@aliyun.com

作者简介: 戴东方（1984—），女，主治医生；

引用本文:

戴东方，陈德玉，李小琴，顾汉刚，王德强. 胃癌组织DNA拓扑异构酶2α等8种分子的蛋白表达与脉管侵犯的关系[J]. 江苏大学学报:医学版, 2018, 28(02): 149-153. DAI Dong-fang, CHEN De-yu, LI Xiao-qin, GU Han-gang, WANG De-qiang. Relationship between protein expression of eight molecules including DNA topoisomerase 2α and lymphovascular invasion in gastric cancer patients. Journal of Jiangsu University(Medicine Edition), 2018, 28(02): 149-153.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2018/V28/I02/149

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015\[J\]. CA Cancer J Clin, 2016, 66(2):115-132.
［2］Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012\[J\] .CA Cancer J Clin,2015,65(2):87-108.
［3］Ajani JA, D′Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology\[J\]. J Natl Compr Canc Netw, 2016, 14(10):1286-1312.
［4］Zhao LY, Chen XL, Wang YG, et al. A new predictive model combined of tumor size, lymph nodes count and lymphovascular invasion for survival prognosis in patients with lymph nodenegative gastric cancer\[J\]. Oncotarget, 2016,7(44):72300-72310.
［5］Li P, He HQ, Zhu CM, et al. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China\[J\]. BMC Cancer, 2015,15:370.
［6］Lee JH, Kim MG, Jung MS, et al. Prognostic significance of lymphovascular invasion in nodenegative gastric cancer\[J\]. World J Surg, 2015,39(3):732-739.
［7］Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation\[J\]. Mod Pathol, 2011,24(12):1545-1552.
［8］Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology\[J\]. J Clin Oncol,2017,35(4):446-464.
［9］Li JC, Yang XR, Sun HX, et al. Upregulation of Kr ppellike factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma\[J\]. Gastroenterology, 2010,139(6):2146-2157.
［10］del Casar JM, Corte MD, Alvarez A, et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance\[J\]. J Cancer Res Clin Oncol, 2008,134(2):153-161.
［11］Kim JH, Park SS, Park SH, et al. Clinical significance of immunohistochemicallyidentified lymphatic and/or blood vessel tumor invasion in gastric cancer\[J\]. J Surg Res, 2010,162(2):177-183.
［12］Zhang S, Zhang D, Gong M, et al. High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer\[J\].BMC Cancer,2017,17(1):335.
［13］Yuan H, Dong Q, Zheng B, et al. Lymphovascular invasion is a high risk factor for stage Ⅰ/Ⅱ colorectal cancer: a systematic review and metaanalysis\[J\].Oncotarget,2017,8(28): 46565-46579.
［14］Kinoshita T, Ohtsuka T, Yotsukura M, et al. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage Ⅰ adenocarcinoma and squamous cell carcinoma of the lung\[J\]. J Thorac Oncol, 2015,10(4):619-628.
［15］Gresta LT, RodriguesJunior IA, de Castro LP, et al. Assessment of vascular invasion in gastric cancer: a comparative study\[J\]. World J Gastroenterol, 2013,19(24):3761-3769.
［16］Du CY, Chen JG, Zhou Y, et al. Impact of lymphatic and/or blood vessel invasion in stage Ⅱ gastric cancer\[J\]. World J Gastroenterol, 2012,18(27):3610-3616.
［17］Baxter J, Sen N, Martínez VL, et al. Positive supercoiling of mitotic DNA drives decatenation by topoisomerase Ⅱ in eukaryotes\[J\]. Science, 2011, 331(6022):1328-1332.
［18］Li X, Dong W, Qu X, et al. Molecular dysexpression in gastric cancer revealed by integrated analysis of transcriptome data\[J\]. Oncol Lett,2017，13(5):3177-3185.
［19］Wang Y. Transcriptional regulatory network analysis for gastric cancer based on mRNA microarray\[J\]. Pathol Oncol Res,2017, 23(4):785-791.
［20］Terashima M, Ichikawa W, Ochiai A, et al. TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage Ⅱ/Ⅲ gastric cancer patients enrolled in the ACTSGC study\[J\]. Oncotarget, 2017, 8(34):57574-57582.
［21］Ejlertsen B, Tuxen MK, Jakobsen EH, et al. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2Anormal breast cancer: DBCG 07READ, an openlabel, phase Ⅲ, randomized trial\[J\]. J Clin Oncol, 2017,35（23）：2639-2646.
［22］Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer\[J\]. N Engl J Med,2006,355(1):11-20.
［23］Sumpter K, HarperWynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF\[J\]. Br J Cancer, 2005,92(11):1976-1983.
［24］Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer\[J\]. N Engl J Med,2008,358(1):36-46.